Arrowhead Pharmaceuticals (NASDAQ:ARWR) Reaches New 1-Year Low - Time to Sell?

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) hit a new 52-week low on Wednesday . The stock traded as low as $14.10 and last traded at $14.18, with a volume of 288286 shares traded. The stock had previously closed at $14.73.

Analyst Upgrades and Downgrades

ARWR has been the subject of several analyst reports. B. Riley reissued a "buy" rating and set a $38.00 price target (down previously from $51.00) on shares of Arrowhead Pharmaceuticals in a report on Friday, February 14th. HC Wainwright restated a "buy" rating and issued a $80.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, February 12th. StockNews.com raised Arrowhead Pharmaceuticals to a "sell" rating in a report on Friday, December 20th. Chardan Capital restated a "buy" rating and issued a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 11th. Finally, Royal Bank of Canada reissued an "outperform" rating and issued a $42.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, February 11th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $41.44.

Arrowhead Pharmaceuticals Stock Performance

The company's 50-day moving average price is $18.13 and its two-hundred day moving average price is $19.61. The company has a market cap of $1.90 billion, a P/E ratio of -2.67 and a beta of 0.92. The company has a current ratio of 6.09, a quick ratio of 6.09 and a debt-to-equity ratio of 7.27.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last issued its earnings results on Monday, February 10th. The biotechnology company reported ($1.39) earnings per share for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.97). As a group, equities analysts forecast that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current year.

Insider Buying and Selling

In other Arrowhead Pharmaceuticals news, CEO Christopher Richard Anzalone sold 51,425 shares of the firm's stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $15.07, for a total value of $774,974.75. Following the completion of the transaction, the chief executive officer now directly owns 4,062,377 shares in the company, valued at $61,220,021.39. This trade represents a 1.25 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, COO Patrick O'brien sold 29,184 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $19.82, for a total transaction of $578,426.88. Following the completion of the transaction, the chief operating officer now directly owns 535,201 shares in the company, valued at approximately $10,607,683.82. This trade represents a 5.17 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 286,317 shares of company stock worth $5,049,735 in the last three months. 4.30% of the stock is currently owned by insiders.

Institutional Trading of Arrowhead Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the business. Intech Investment Management LLC purchased a new stake in Arrowhead Pharmaceuticals in the 3rd quarter worth about $659,000. Charles Schwab Investment Management Inc. lifted its position in shares of Arrowhead Pharmaceuticals by 1.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,006,935 shares of the biotechnology company's stock worth $19,504,000 after purchasing an additional 12,574 shares in the last quarter. Fisher Asset Management LLC boosted its holdings in shares of Arrowhead Pharmaceuticals by 941.0% during the third quarter. Fisher Asset Management LLC now owns 122,260 shares of the biotechnology company's stock worth $2,368,000 after purchasing an additional 110,516 shares during the period. Quantbot Technologies LP purchased a new position in Arrowhead Pharmaceuticals during the third quarter valued at approximately $149,000. Finally, BNP Paribas Financial Markets increased its stake in Arrowhead Pharmaceuticals by 40.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 55,188 shares of the biotechnology company's stock valued at $1,069,000 after buying an additional 15,784 shares during the period. Institutional investors and hedge funds own 62.61% of the company's stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.